Novo Nordisk Shares Rally on Unprecedented Demand for Oral Weight-Loss Pill

Copenhagen, Wednesday, 6 May 2026.
Driven by the fastest adoption in weight-loss drug history, Novo Nordisk’s new oral pill hit 200,000 weekly prescriptions, sending shares soaring and prompting an upgraded 2026 financial outlook.